TY  - JOUR
AU  - Breitkreutz, Iris
AU  - Becker, Natalia
AU  - Benner, Axel
AU  - Kosely, Florentina
AU  - Heining, Christoph
AU  - Hillengass, Jens
AU  - Egerer, Gerlinde
AU  - Ho, Anthony D
AU  - Goldschmidt, Hartmut
AU  - Raab, Marc-Steffen
TI  - Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
JO  - Hematological oncology
VL  - 34
IS  - 4
SN  - 0278-0232
CY  - New York, NY [u.a.]
PB  - Wiley Interscience
M1  - DKFZ-2017-01682
SP  - 200 - 207
PY  - 2016
AB  - Therapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m(2) , day 1 and 2) followed by autologous blood stem cell support (ASCS) would improve bone marrow function with low post-transplant toxicity in patients with severely impaired haematopoiesis. We analyzed 28 consecutive myeloma patients, with a median of three prior lines of therapy (range 2-7), who had relapsed from the last treatment with very limited bone marrow function and were therefore ineligible for conventional chemotherapy, novel agents or trial enrolment. Dose-intensified bendamustine with ASCS improved haematopoiesis as reflected by increased platelet counts (median 40/nl vs 94/nl, p = 0.0004) and white blood cell counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The median time until engraftment of platelets (>50/nl) was 11 days (0-24 days) and of white cell counts (>1.0/nl) 0 days (0-24 days). At least, a minimal response was achieved in 36
KW  - Bendamustine Hydrochloride (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25784529
DO  - DOI:10.1002/hon.2199
UR  - https://inrepo02.dkfz.de/record/125556
ER  -